Serevent Diskus (salmeterol xinafoate inhalation powder)

Airsupra is an anti-inflammatory rescue medication that can treat the symptoms of asthma while helping to prevent an attack.

Sotatercept is a first-in-class therapy to treat the rare disease pulmonary arterial hypertension. The FDA has assigned a target action date of March 26, 2024.

If approved, Ofev would be the first approved treatment for children and adolescents with fibrosing interstitial lung disease. A decision is expected in the fourth quarter of this year.

Tezspire is a biologic that specifically targets the inflammation associated with asthma.

Airsupra is the first rescue medication to manage both the symptoms and the inflammation associated with asthma.